Allopurinol and the Risk of Diabetic Macular Edema among U.S. Veterans with Type 2 Diabetes.
Allopurinol and the Risk of Diabetic Macular Edema among U.S. Veterans with Type 2 Diabetes.
复制标题
别嘌呤醇与美国 2 型糖尿病退伍军人中糖尿病性黄斑水肿的风险。
DOI：
10.1080/09273948.2023.2170886
复制
发表时间：
2023
影响因子：
3.3
通讯作者：
Ambati,Jayakrishna
中科院分区：
文献类型：
--
作者：
Sutton,SScott;Magagnoli,Joseph;Cummings,TammyH;Hardin,JamesW;Ambati,Jayakrishna
背景别嘌醇通过抑制黄嘌呤氧化酶、随后的炎性细胞因子释放以及由此导致的血-视网膜屏障的破坏，可能限制炎症驱动的糖尿病黄斑水肿(DME)。方法我们采用回顾性队列研究的方法，在美国2型糖尿病退伍军人中检验了别嘌醇与DME的关系。结果概率得分匹配的COX模型显示，别嘌醇可降低糖尿病视网膜病变风险24.6%(HR=0.754；95%CI=0.684-0.831)。结论别嘌醇可降低糖尿病患者视力障碍的发病风险。进一步研究别嘌醇对DME的影响是有必要的。
BackgroundBy inhibiting xanthine oxidase, subsequent inflammatory cytokine release and the resulting breakdown of the blood–retina barrier, allopurinol may limit the inflammation-driving diabetic macular edema (DME).MethodsWe examined the relationship between allopurinol and DME among type 2 diabetic United States veterans using a retrospective cohort study. We used propensity score matching and Cox hazard models to estimate the risk of DME.ResultsPropensity score-matched Cox models revealed allopurinol was associated with a 24.6% reduction in the risk of DME (HR = 0.754; 95% CI = (0.684–0.831)).ConclusionAllopurinol could reduce the risk of DME, one of the major causes of visual disturbance among diabetic patients. Further research into the effects of allopurinol on DME is warranted.